Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation 6.375% Mandatory Convertible Preferred Stock (BRKRP) filings page on Stock Titan is designed to organize and interpret regulatory information related to this preferred equity and its issuer, Bruker Corporation. While no specific SEC filings are listed here in the available data, Bruker’s public communications provide important context for understanding BRKRP as a mandatory convertible preferred security with a stated dividend rate of 6.375%.
In its announcements, Bruker has disclosed a quarterly cash dividend of $3.6745 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. Regulatory filings associated with such securities typically include the original registration statements and prospectus describing the preferred stock terms, including dividend provisions, conversion mechanics, and rights relative to common stock. Periodic reports often discuss capital structure, preferred stock dividends, and any changes affecting holders of BRKRP.
For a company like Bruker, which emphasizes high-performance scientific instruments and analytical and diagnostic solutions, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can also provide narrative and quantitative detail on its operations in post-genomic life science research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, semiconductor metrology, and clinical and molecular diagnostics. These documents help place the BRKRP preferred stock within the broader financial and operational picture of the issuer.
On Stock Titan, AI-powered tools can assist in summarizing lengthy filings, highlighting sections that relate to preferred stock terms, dividend policies, and capital structure, as well as identifying disclosures relevant to Bruker’s scientific and diagnostic activities. This can help readers more quickly locate information that matters for evaluating BRKRP and understanding how regulatory disclosures reflect Bruker’s business and financing choices.
Bruker Corporation has expanded its Board of Directors to twelve members and appointed Thierry L. Bernard as a Class III director, effective April 1, 2026. He will serve until the 2027 Annual Meeting of Stockholders.
Bernard is currently CEO and Managing Director of QIAGEN N.V., with a previously announced transition plan under which he will step down once a successor is appointed. His background spans senior roles at bioMérieux and other international life-science companies, as well as board leadership at AdvaMedDx and Neogen Corporation. His compensation as a non-employee director will match Bruker’s existing director compensation program, and the company states there are no related-party transactions requiring disclosure. Bruker will later disclose his Board committee assignments.
Bruker Corp — Amendment No. 8 to a Schedule 13G/A was filed reporting that The Vanguard Group beneficially owns 0 shares of Bruker Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or business divisions to report ownership separately. The filer states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries/divisions. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
BRUKER CORP executive Mark Munch reported an option exercise and share sale. On March 13, he exercised stock options for 2,000 shares of common stock at $22.19 per share, then sold 2,000 shares of common stock at $35.44 per share.
Following these transactions, he directly held 128,443 shares of common stock. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, routine liquidity event rather than an opportunistic trade.
Mark R Munch reported sales of Common stock under Rule 144, including multiple transactions dated 01/05/2026, 01/12/2026, 01/15/2026, 02/13/2026, and a stock option exercise on 03/13/2026.
The filing lists individual dispositions of 33,843 shares on 01/05/2026 for $1,680,704, 7,000 shares on 01/12/2026 for $385,000, 2,000 shares on 01/15/2026 for $98,400, and 2,000 shares on 02/13/2026 for $73,880, plus a 2,000-share stock option exercise on 03/13/2026 paid in cash.
Bruker Corp Schedule 13G/A filing reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 16,130,961 shares of common stock, representing 10.6% of the class. The filing breaks ownership by reporting person: Orbis Investment Management Ltd holds 15,197,866 shares; Orbis Investment Management (U.S.), L.P. holds 904,773; Allan Gray Australia Pty Ltd holds 28,322. The reporting persons state regulatory equivalence for non‑U.S. filers and disclaim group beneficial ownership.
Bruker Corporation files its annual report describing a global business built around four segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, focused on advanced scientific instruments and superconducting materials. The company serves life science, biopharma, materials, semiconductor, microbiology, diagnostics, and government markets with NMR, mass spectrometry, X-ray, microscopy, spatial biology, diagnostics, and superconducting technologies.
Bruker reports an aggregate market value of non‑affiliate stock of $4,251,097,535 as of June 30, 2025, with 152,219,250 common shares and 2,760,000 Series A mandatory convertible preferred shares outstanding as of February 20, 2026. Backlog was about $2,569.4 million at December 31, 2025, and the workforce totaled approximately 11,085 employees worldwide. Key risks highlighted include supply chain constraints, tariffs, reduced U.S. and Chinese research funding, geopolitical tensions, currency fluctuations, competition, and potential impairment of goodwill and other long‑lived assets.
Bruker Corporation announced board changes and a new dividend. Director Dr. Cynthia M. Friend will not stand for re-election as a Class II director when her term ends at the 2026 Annual Meeting, and her decision is stated as not due to any disagreement with the company. She will continue to serve until then.
On February 19, 2026, Jack Phillips stepped down as a Class III director and was immediately re-elected as a Class II director, with his board service deemed continuous from January 1, 2026, and his compensation and benefits unchanged. The board also declared a quarterly cash dividend of $0.05 per share on Bruker’s common stock, payable on April 7, 2026 to shareholders of record as of March 23, 2026.
FRANCIS LAURA reported acquisition or exercise transactions in this Form 4 filing.
Bruker Corporation director Laura Francis received an equity award of 4,520 shares of Common Stock in the form of restricted stock units on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027. After this grant, she holds 9,018 shares directly.
Bruker Corp director Jack Phillips reported an equity award. On February 15, 2026, he acquired 4,520 shares of Common Stock through a grant classified as a “grant, award, or other acquisition.” The footnote explains this is represented by Restricted Stock Units that will vest in a single installment on February 15, 2027, when each unit will convert into one share of Common Stock. Following this award, his directly held position is reported as 4,520 shares.
BRUKER CORP director John A. Ornell received an equity grant of 4,520 shares of Common Stock in the form of restricted stock units. The award was reported at no cash purchase price and increased his directly held stake to 39,732 shares after the transaction.
The RSUs will vest in a single installment on February 15, 2027. On that vesting date, each restricted stock unit will automatically convert into one share of Bruker common stock, aligning the director’s compensation with future company performance over the vesting period.